Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526338 · ClinicalTrials.gov registry record · Phase 2
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
A Phase 2 study of Hepatocellular Carcinoma, sponsored by Robert C. Martin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 1
- Study location
NCT06526338: Recruiting Phase 2 study of Hepatocellular Carcinoma, sponsored by Robert C. Martin.
NCT06526338 is a Phase 2 study of Hepatocellular Carcinoma that is actively recruiting participants, run by Robert C. Martin. The registered enrollment target is 126 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06526338, a Phase 2 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Robert C. Martin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a single injection of IP-001 as adjuvant therapy after local ablation or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).
Primary Outcome
Radiological assessments (Triphasic CT or MRI) of the chest, abdomen and pelvis will occur every 12 weeks for the first 2 years, then every 24 weeks thereafter. Recurrence will be determined by the investigator's radiological review per RECIST v1.1
Conditions Studied
Interventions
- DRUG 1.0% IP-001 for injection
- PROCEDURE Surgical Resection and Local Ablation
- PROCEDURE Local Ablation Alone
Study Locations (1)
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2024-07-24 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
What NCT06526338 shows while recruiting
NCT06526338 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which 1.0% IP-001 for injection is the first listed.
NCT06526338 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06526338 about?
NCT06526338 is a clinical study titled "Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone". The purpose of this study is to evaluate the safety and efficacy of a single injection of IP-001 as adjuvant therapy after local ablation or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).
What is the current status of trial NCT06526338?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2024-07-24. Estimated completion is 2030-12.
What conditions does trial NCT06526338 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06526338?
The interventions under investigation include: 1.0% IP-001 for injection (DRUG), Surgical Resection and Local Ablation (PROCEDURE), Local Ablation Alone (PROCEDURE).
Who is sponsoring clinical trial NCT06526338?
This trial is sponsored by Robert C. Martin, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526338 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06526338's enrollment target sits among peer trials
126 50th of 145 higher than 95 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI